Market accessOfficial

Estonia receives 53,000 Vaxigrip doses, about 20,000 open to all

🇪🇪 Ravimiamet · Wed 11 Nov 2026

Ravimiamet says the new influenza vaccine batch is split between pre-booked institutions and the open market, and warns that November supplies will not cover everyone who wants a jab.

Estonia received 53,000 doses of the Vaxigrip influenza vaccine this week, the Estonian State Agency of Medicines (Ravimiamet) reported on 11 November 2026. Just over 20,000 of those doses are intended for anyone who wants vaccination, not only people in risk groups.

That portion is divided between institutions that signed pre-booking agreements for immunisation supplies and the open market. Ravimiamet said the vaccine would reach pharmacies and vaccination centres during the week. People are directed to contact their family doctor, or to book through the health portal, a healthcare provider's website or the vaccination pharmacy website vaktsineeriapteegis.ee.

The agency cautioned that the quantities arriving in November will definitely not be enough for everyone who wants vaccination. According to the manufacturer's current data, about 40% of this season's Influvac, whose marketing authorisation holder is Viatris Healthcare Limited, is due in Estonia at the start of January. That volume is earmarked for anyone who wishes to be vaccinated.

Of the nearly 93,000 doses that reached risk groups at the start of November, one tenth has been used so far, and active registration continues. Fluenz, a nasal spray vaccine, is also available to children and adolescents on a paid basis.

Ravimiamet noted that influenza incidence in Estonia usually peaks in late December or January. Protection develops about two to three weeks after vaccination and lasts at least six months. The agency also urged people to follow general advice on avoiding infection during the virus season.

What it means for your team

  • Supply teams should note the staggered delivery: Vaxigrip is arriving now, while roughly 40% of the Influvac volume is expected in early January.
  • Distributors and pharmacies should plan for demand outstripping November stock for the general population, as Ravimiamet has said openly.
  • Uptake of the risk-group allocation stands at about 10% of nearly 93,000 doses, a figure that can be used to track early-season utilisation.
  • Fluenz is available only as a paid option for children and adolescents, which matters for access planning in that age group.

Official source: Ravimiamet ↗

Article written by VigiEye from the official source (Ravimiamet). AI-assisted; check the source before acting.

More Market access All →